Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 645 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Process-level Clear all
Completed Not applicable Interventional

A Mediation Analysis Investigating Dry Needling Treatment Mechanisms in a Chronic Low Back Pain Population

NCT06940492
View directory record Official record
Conditions
Chronic Low Back Pain (CLBP)
Interventions
Dry needling
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 18, 2026, 5:49 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Nutrition for Precision Health, Powered by the All of Us

NCT05701657
View directory record Official record
Conditions
Nutrition, Health, Dietary Habits
Interventions
Diet A, Diet B, Diet C
Other
Lead sponsor
RTI International
Other
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Davis, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 5:49 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

NCT06839456
View directory record Official record
Conditions
Leukemia, High Risk Acute Lymphoblastic Leukemia, High Risk Acute Myeloid Leukemia, Relapse Leukemia, MDS (Myelodysplastic Syndrome), Relapsed Non-Hodgkin Lymphoma, Acquired Aplastic Anemia, Inherited BMF Syndrome, Immunodeficiency, Primary Immune Regulatory Disorder, Hemoglobinopathies, Bone Marrow Failure, Inborn Errors of Metabolism, HLH
Interventions
Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3, Phase 2 Maximum Tolerated Dose determined in Phase 1, Phase 2 Established Dose from prior study, NCT03810196
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Month to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 18, 2026, 5:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Adaptive Implementation Intervention for VA Suicide Risk Identification Strategy

NCT04243330
View directory record Official record
Conditions
Suicide
Interventions
Audit and Feedback, External Facilitation
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 18, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants

NCT05981976
View directory record Official record
Conditions
Healthy Participants
Interventions
Abatacept
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
3
States / cities
Cypress, California • Miami, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 18, 2026, 5:49 AM EDT
Completed Not applicable Interventional

A Randomized Trial: Changing Behavior in Post-Angioplasty Patients

NCT00248846
View directory record Official record
Conditions
Angioplasty Patients
Interventions
Intervention Group
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 110 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 18, 2026, 5:49 AM EDT
Terminated Not applicable Interventional

A Trial Comparing Three Orthobiologic Therapies on Atrophied Multifidus Muscles in Patients With Low Back Pain

NCT03618979
View directory record Official record
Conditions
Low Back Pain
Interventions
PPP treatment, PRP treatment, PRP and PL Combo treatment
Biological
Lead sponsor
Regenexx, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Broomfield, Colorado • Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 18, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus

NCT00880789
View directory record Official record
Conditions
Cytomegalovirus Infection, Adenovirus Infection
Interventions
CMV/AdV specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 18, 2026, 5:49 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells

NCT00703222
View directory record Official record
Conditions
Neuroblastoma
Interventions
SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP, SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 18, 2026, 5:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia

NCT00906945
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
G-CSF, Plerixafor, Mitoxantrone, Etoposide, Cytarabine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 18, 2026, 5:49 AM EDT
Completed Not applicable Interventional Results available

TOP Implementation Project

NCT02737098
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Enhanced Implementation Strategy, Standard Implementation Strategy
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
Little Rock, Arkansas • San Diego, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 18, 2026, 5:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Interventions to Help More Low-income Smokers Quit

NCT04311983
View directory record Official record
Conditions
Tobacco Use Cessation, Smoking Behaviors, Health Disparity
Interventions
Tobacco Quitline, Smoke Free Home
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years and older
Enrollment
1,973 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 18, 2026, 5:49 AM EDT
Recruiting Phase 2 Interventional

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

NCT07493538
View directory record Official record
Conditions
AML, MDS, Acute Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Treosulfan, Fludarabine, Total Body Irradiation, Tacrolimus, Mycophenolate Mofetil, Cyclophosphamid, Stem Cell Infusion
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
2 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 18, 2026, 5:49 AM EDT
Recruiting Phase 2 Interventional

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

NCT06315309
View directory record Official record
Conditions
GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions
ATG Combined with Tacrolimus and Mini Methotrexate
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 18, 2026, 5:49 AM EDT
Completed Early Phase 1 Interventional

Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation

NCT00612274
View directory record Official record
Conditions
Stem Cell Transplantation
Interventions
tacrolimus, Sirolimus, Methotrexate
Drug
Lead sponsor
Yale University
Other
Eligibility
16 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 18, 2026, 5:49 AM EDT
Enrolling by invitation Not applicable Interventional

Effectiveness of Interventions to Improve Resiliency & Burnout in Behavioral Health Residential Staff

NCT05806112
View directory record Official record
Conditions
Burnout, Stress, Coping Skills, Depression, Anxiety, Physical Inactivity, Sleep, Healthy Eating
Interventions
Resiliency Training, Task Sharing, Workplace Improvement Learning Collaborative
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 18, 2026, 5:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).

NCT01835587
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
CC-486
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
New York, New York • Cleveland, Ohio • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 18, 2026, 5:49 AM EDT
Enrolling by invitation Not applicable Interventional

Penn Family Screening for Familial Hypercholesterolemia

NCT05750667
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
Cascade screening
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 18, 2026, 5:49 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy

NCT06851767
View directory record Official record
Conditions
X-linked Severe Combined Immunodeficiency, X-SCID, XSCID
Interventions
Plerixafor, Filgrastim, Palifermin, Busulfan, Base-edited hematopoietic stem and progenitor cells
Genetic · Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 99 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 5:49 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Providing "Good Sleep" for ICU Sedation

NCT01342328
View directory record Official record
Conditions
Sleep Disorders
Interventions
Normal saline infusion, Dexmedetomidine, Propofol
Other · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 18, 2026, 5:49 AM EDT
Recruiting Phase 1 Interventional

Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

NCT01555892
View directory record Official record
Conditions
Hodgkin's Disease, Non-Hodgkin's Lymphoma, Lymphoproliferative Disease, Lymphoma
Interventions
EBV-specific T cells: A, EBV-specific T cells: B
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 18, 2026, 5:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preliminary Effect of Food Processing and Sweeteners on Glycemic and Metabolic Measures

NCT05658757
View directory record Official record
Conditions
Blood Sugar; High, Blood Pressure, Dietary Habits
Interventions
Regular sweetened commercial foods, Allulose sweetened commercial foods, Whole and minimally processed and sweetened foods
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
20 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 18, 2026, 5:49 AM EDT
Active, not recruiting Phase 1 Interventional

Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors

NCT02789228
View directory record Official record
Conditions
Solid Tumors
Interventions
Tumor associated antigen lymphocytes (TAA-CTL)
Biological
Lead sponsor
Children's National Research Institute
Other
Eligibility
6 Months to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 18, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Results available

Phase I Study of APX005M in Pediatric Central Nervous System Tumors

NCT03389802
View directory record Official record
Conditions
Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS), CNS Primary Tumor, Not Otherwise Specified (NOS), Ependymoma, Not Otherwise Specified (NOS), Diffuse Intrinsic Pontine Gliomas (DIPG), Medulloblastoma
Interventions
APX005M treatment for recurrent or refractory primary malignant CNS tumor patients, APX005M treatment for newly diagnosed DIPG patients
Biological
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
1 Year to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 18, 2026, 5:49 AM EDT